Filter
580
Filtered Results: 580
Text search:
COVID-19
and
pregnancy
Featured
Recommendations
76
New Publications
18
Language
Document type
Studies & Reports
215
Guidelines
172
Strategic & Response Plan
56
Fact sheets
49
Manuals
42
Situation Updates
13
Training Material
10
No document type
9
Infographics
7
Resource Platforms
3
Videos
2
Brochures
1
App
1
Countries / Regions
Global
59
India
22
Latin America and the Carribbean
21
South Africa
16
Brazil
15
Western and Central Europe
13
Russia
12
Syria
11
Ukraine
11
Nigeria
9
Kenya
9
South–East Asia Region
9
East and Southern Africa
8
Middle East and North Africa
8
Bangladesh
7
Malawi
7
Eastern Europe and Central Asia
6
South Sudan
5
Yemen
5
Africa
5
Congo, Democratic Republic of
4
Ethiopia
4
Haiti
4
Nepal
4
Afghanistan
4
Zambia
4
Western Pacific Region
4
Uganda
3
Philippines
3
Germany
3
Colombia
3
West and Central Africa
3
Venezuela
3
Ghana
2
Zimbabwe
2
Somalia
2
Pakistan
2
Lebanon
2
Mozambique
2
Argentina
2
Peru
2
Ecuador
2
Bolivia
2
Myanmar / Burma
2
Sri Lanka
2
Palestine
2
Laos
2
North America
2
Sierra Leone
1
Senegal
1
Côte d’Ivoire / Ivory Coast
1
USA
1
Cameroon
1
Turkey
1
Cambodia
1
Thailand
1
Rwanda
1
Indonesia
1
Sudan
1
Central African Republic
1
Namibia
1
Eswatini/ Swaziland
1
Honduras
1
Botswana
1
Mexico
1
Chile
1
Asia
1
Fiji
1
Eastern Europe
1
Congo-Brazzaville
1
Bulgaria
1
Vietnam
1
Jamaica
1
France
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
216
Women & Child Health
53
Clinical Guidelines
46
Public Health
38
Key Resources
13
Capacity Building
10
Pharmacy & Technologies
4
Annual Report MEDBOX
1
Toolboxes
COVID-19
279
HIV
44
Caregiver
30
NCDs
24
Conflict
21
Mental Health
19
Planetary Health
17
Refugee
13
Rapid Response
10
TB
10
Global Health Education
10
Pharmacy
10
Natural Hazards
8
Health Financing Toolbox
7
NTDs
6
AMR
3
Disability
2
Zika
2
Ebola
1
Cholera
1
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-... Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
A series of data syntheses from the RCCE Collective Service. It focuses on public perceptions of the COVID-19 vaccinations, bringing together 66 data sources from quantitative surveys across 107 cou...
April 2020
This Guidance Note offers a list of recommendations based on a combination of WHO guidelines, good practice and expert advice based on the latest scientific research. The situation with COVID...-19 is evolving rapidly and the guidance will continue to be updated if and when new evidence or information becomes available.
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by ...
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
Across Zimbabwe, 7 million people in urban and rural areas are in urgent need of humanitarian assistance, compared to 5.5 million in August 2019. Since the launch of the Revised Humanitarian Appeal in August 2019, circumstances for millions of Zimba...
12 May 2021. This third survey in the series shows that the COVID-19 pandemic continues to impact societies, not only in terms of health, but also social ... economic conditions and day-to-day life
The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID...
As information about COVID-19 is rapidly evolving, it can be challenging to navigate and synthesize all of the information. The purpose of this doc...
Mapping of Communication Resources COVID-19
recommended
This resource mapping contains signposting and direct links to a range of resource sites and content online; this includes information about the main sources for trustworthy information about the pa...
The primary focus of the plan continues to be prevention, preparedness and treatment of the the Novel Coronavirus (COVID-19) outbreak. Central to t...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-... Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
The brief concludes that sustaining the continuity of EHS requires policies that ensure a whole-society and systems strengthening approach. This involves increased health care investment, community engagement, disease control regulations, ... multisector approaches to improve resilience, EHS quality, and equity.
24 May 2021; Guidance for vaccinators on how to store, prepare, draw up and administer COVID-19 vaccines Updated May 2021 · Western Cape Edition
...
The updates are based on evidence emerging from the: Ongoing monitoring of the disease. Protection that the population already developed against COVID-19 through previous infection or vaccination. E...
- Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition
Coronavirus disease 2019 (...-19) has a wide range of documented effects. It directly causes death and disability for some people infected. However, disruption to essential health services, resources allocated to mitigation and therefore away from essential health service delivery, and the overall impact on the economy and society must also be considered within the response to COVID-19. Understanding the magnitude of all of these effects is an essential part of developing mitigation polices.
Several epidemiological models have been created to assess the potential impact of disruptions to essential health services caused by COVID-19 on morbidity and mortality from conditions other than COVID-19 illness. This guide presents models that have been used to assess these indirect impacts. The effects have been studied in various settings, using a variety of models.
The guide is intended for people who need to understand what the models say, their construction and their underlying assumptions, or need to use models and their outcomes for planning and programme development and to support policy decisions for a country or region.
Guidelines on Management of COVID-19 in Kenya
recommended
It has been over a year since Kenya identified the first case of COVID-19 in the country. The Government formed the National COVID-... task force, which supported the country's response through multi-sectoral technical working groups on testing, case management, risk communication and community engagement among others. An earlier version of the COVID case management guideline was released in April 2020 and capacity building of health care workers on diagnosis and treatment of COVID-19 was quickly carried out, even as counties prepared themselves by setting up isolation centres and supplies
This policy paper underscores that, although children do not represent a high-risk group for direct COVID-19 fatality, the pandemic posts far-reaching secondary impacts that heighten risks to Africa...
Countries around the world are facing the challenge of increased demand for care of people with COVID-19, compounded by fear, misinformation and li...
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document ... annexes referenced below.
This document has been updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
